Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC
March 8th 2024David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.
Read More
Dr. Park on the Increasing Use of Biomarker Testing and Radiotheranostics in Prostate Cancer
March 6th 2023Chandler Park, MD, MSc, FACP, discusses how the emerging field of radiotheranostics and increasing utilization of biomarker testing will improve the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More